Johnson & Johnson Reports Promising OrigAMI-4 Trial Results
Johnson & Johnson has unveiled new data from its Phase 1b/2 OrigAMI-4 study, demonstrating that first-line treatment with investigational subcutaneous amivantamab and…
Read More...
Read More...
